Completed PHASE2 INTERVENTIONAL 2-arm NCT00215826

Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers

A Randomized, Dose-ranging Study of Alferon® LDO {Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)} in Normal Volunteers and/or Asymptomatic Subjects With Exposure to a Person Known to Have SARS or Possible SARS

Sponsor: AIM ImmunoTech Inc.

Conditions Severe Acute Respiratory Syndrome

Interventions Alferon LDO

Updated 7 times since 2017 Last updated: Apr 16, 2013 Started: Nov 30, 2004 Primary completion: Apr 30, 2006 Completion: Apr 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Severe Acute Respiratory Syndrome and is currently completed. AIM ImmunoTech Inc. leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Feb 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Feb 2020 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Nov 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AIM ImmunoTech Inc.

Data source: AIM ImmunoTech Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lai Chi Kok, Hong Kong